105565-55-7
105565-55-7
Chemical Structure
BMY-14802 hydrochloride
Synonym(s): BMY-14802-1; BMS 181100 hydrochloride
- CAS No.: 105565-55-7
- Formula:C18H23ClF2N4O
- Molecular Weight:384.85
IUPAC Name: 1-(4-fluorophenyl)-4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)butan-1-ol hydrochloride
InChIKey: NIBVEFRJDFVQLM-UHFFFAOYSA-N
SMILES: [H]Cl.OC(C1=CC=C(F)C=C1)CCCN2CCN(C3=NC=C(F)C=N3)CC2
Biological Activity: BMY-14802 hydrochloride (BMY-14802-1) is a selective and orally active sigma receptor antagonist with an IC50 of 112 nM. BMY-14802 hydrochloride is also a 5-HT1A and adrenergic α1 receptors agonist. BMY-14802 hydrochloride has antipsychotic effects[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
BMY-14802 hydrochloride | 98.02% | BMY-14802 hydrochloride (BMY-14802-1) is a selective and orally active sigma receptor antagonist with an IC50 of 112 nM. BMY-14802 hydrochloride is also a 5-HT1A and adrenergic α1 receptors agonist. BMY-14802 hydrochloride has antipsychotic effects. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
BMY-14802 hydrochloride (Standard) | ≥98% | BMY-14802 hydrochloride (Standard) is the analytical standard of BMY-14802 (hydrochloride) (HY-108509). This product is intended for research and analytical applications. BMY-14802 hydrochloride (BMY-14802-1) is a selective and orally active sigma receptor antagonist with an IC50 of 112 nM. BMY-14802 hydrochloride is also a 5-HT1A and adrenergic α1 receptors agonist. BMY-14802 hydrochloride has antipsychotic effects. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. J P Yevich, et al. Synthesis and biological characterization of alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol and analogues as potential atypical antipsychotic agents. J Med Chem. 1992 Nov 27;35(24):4516-25. [Content Brief]
- [2]. Nirmal Bhide, et al. The effects of BMY-14802 against L-DOPA- and dopamine agonist-induced dyskinesia in the hemiparkinsonian rat. Psychopharmacology (Berl). 2013 Jun;227(3):533-44. [Content Brief]
- [3]. Melanie A Paquette, et al. The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanism. Psychopharmacology (Berl). 2009 Jul;204(4):743-54. [Content Brief]
